What evaluation and laboratory tests are indicated for a 14-year-old with short stature?

Evaluation and Laboratory Testing for a 14-Year-Old with Short Stature

Begin with a comprehensive growth assessment including serial height measurements plotted on CDC growth charts, calculation of mid-parental height, bone age radiograph, and targeted laboratory screening based on growth velocity and clinical features. 1

Initial Growth Analysis

The first critical step is determining whether pathologic short stature is present by evaluating:

• Growth velocity over 4-6 months: Crossing multiple centile lines between ages 3 and early adolescence strongly suggests pathologic causes 1
• Mid-parental height calculation: Compare the patient's height trajectory to genetic potential 1
• Bone age assessment: Obtain left hand and wrist radiograph to determine skeletal maturation 1
• Height measurement: Confirm height is <3rd percentile (>2 standard deviations below mean) using standardized technique 1, 2

Essential Laboratory Screening

For all patients with confirmed pathologic short stature, obtain the following initial bloodwork:

• Complete blood count (CBC): Screen for chronic disease and nutritional deficiencies 1
• Comprehensive metabolic panel: Evaluate renal and hepatic function 1
• Thyroid function tests (TSH, free T4): Rule out hypothyroidism, which must be excluded before proceeding 1
• Erythrocyte sedimentation rate (ESR): Screen for inflammatory conditions 1
• Celiac disease screening: Tissue transglutaminase antibodies with total IgA 1
• IGF-1 and IGFBP-3 levels: Initial screening for growth hormone axis abnormalities 3

Important caveat: Normal IGF-1 does not exclude growth hormone deficiency, particularly in patients with delayed puberty or bone age, as IGF-1 levels must be interpreted in context of pubertal stage 3

Genetic and Chromosomal Testing

Karyotype analysis is essential in all phenotypic females with unexplained short stature to evaluate for Turner syndrome, which accounts for 19% of pathologic short stature cases in genetic referrals 1

Consider chromosomal microarray or genetic testing when:

• Dysmorphic facial features are present (68.2% association with positive genetic findings) 4
• Skeletal abnormalities are identified (61.1% association with positive findings) 4
• Syndromic features or developmental concerns exist 1, 5

The diagnostic yield varies significantly by testing modality: chromosomal microarray yields 16.3%, gene panels 21.6%, and exome sequencing 33.3% overall, with higher yields (50.8%) in syndromic presentations 4

Growth Hormone Deficiency Evaluation

If IGF-1/IGFBP-3 are low or growth velocity is severely impaired (<4 cm/year), proceed with growth hormone stimulation testing:

• Perform two separate provocative tests (peak GH <10 ng/mL on both tests confirms GH deficiency) 6
• Insulin tolerance test first: Higher specificity (78.4%) and accuracy (93.6%) compared to L-dopa test 6
• Consider priming with sex steroids in pubertal-aged patients with delayed puberty to avoid false-positive results 3
• Obtain pituitary MRI if GH deficiency is confirmed to evaluate for structural abnormalities 3

Critical pitfall: In patients with brain tumors or craniopharyngioma, IGF-1 levels do not accurately predict GH deficiency; clinical presentation (linear growth failure, delayed bone age) combined with imaging findings may be sufficient for diagnosis without provocative testing 3

Referral Indications

Refer to pediatric endocrinology when:

• Height velocity is abnormally low despite normal screening labs 2
• IGF-1/IGFBP-3 levels are abnormal 3
• Bone age is significantly delayed (>2 SD) 1
• Growth hormone deficiency is suspected or confirmed 2, 7
• Idiopathic short stature requires management consideration 2

Refer to medical genetics when:

• Dysmorphic features, skeletal dysplasia, or syndromic features are present 1, 5
• Family history suggests genetic etiology 5
• Multiple congenital anomalies exist 1

Common Diagnostic Outcomes

In genetic referral populations, approximately 50% have constitutional delay or familial short stature (non-pathologic), while pathologic causes include chromosomal abnormalities (19%, primarily Turner syndrome), recognized syndromes (3%), and previously unrecognized endocrine causes (2%) 1